Disitamab vedotin

Generic Name: Disitamab vedotin

Drug Type: Biotech

CAS Number: 2136633-23-1

Unique Ingredient Identifier: RB3U3A1S27

Background: Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.

Indication: 用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。

Clinical Trials

RC48-ADC in HER2-low Advanced Breast Cancer

Not Applicable

Recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: Disitamab vedotin

First Posted Date: 2023-04-26

Last Posted Date: 2023-05-09

Lead Sponsor: RenJi Hospital

Target Recruit Count: 36

Registration Number: NCT05831878

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Phase 1

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: RC48-ADC
Drug: Pyrotinib

First Posted Date: 2023-02-27

Last Posted Date: 2023-11-27

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT05745740

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Disitamab Vedotin
Drug: Penpulimab

First Posted Date: 2023-02-13

Last Posted Date: 2023-02-13

Lead Sponsor: West China Hospital

Target Recruit Count: 20

Registration Number: NCT05726175

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Not yet recruiting

Conditions: Advanced Gastroesophageal Junction Adenocarcinoma
Advanced Solid Tumor
HER2
Advanced Gastric Cancer

Interventions: Drug: Disitamab Vedotin

First Posted Date: 2022-12-13

Last Posted Date: 2022-12-16

Lead Sponsor: Shen Lin

Target Recruit Count: 306

Registration Number: NCT05649163

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Disitamab Vedotin
Drug: Sintilimab
Drug: S-1
Procedure: Intraperitoneal chemotherapy with paclitaxel

First Posted Date: 2022-11-25

Last Posted Date: 2022-11-25

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05627414

Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2

Phase 2

Recruiting

Conditions: Salivary Gland Tumors

Interventions: Drug: RC48-ADC

First Posted Date: 2022-11-01

Last Posted Date: 2022-11-01

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 10

Registration Number: NCT05601401

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

Phase 2

Active, not recruiting

Conditions: HER2-positive Gastric Cancer

Interventions: Drug: Disitamab vedotin
Drug: Tislelizumab
Drug: S1

First Posted Date: 2022-10-19

Last Posted Date: 2025-02-07

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 55

Registration Number: NCT05586061

Locations: 🇨🇳
Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳
Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry, Jinan, Shandong, China

and more 4 locations

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Phase 1

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: RC48-ADC
Drug: RC98

First Posted Date: 2022-08-24

Last Posted Date: 2023-12-18

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT05514158

Locations: 🇨🇳
Remegen, Beijing, Beijing, China

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Phase 2

Recruiting

Conditions: Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

Interventions: Drug: Disitamab Vedotin
Drug: Disitamab Vedotin Tislelizumab

First Posted Date: 2022-08-10

Last Posted Date: 2022-08-10

Lead Sponsor: Tianjin Medical University Second Hospital

Target Recruit Count: 176

Registration Number: NCT05495724

Locations: 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Neoplasms

Interventions: Drug: Disitamab vedotin
Drug: Tislelizumab

First Posted Date: 2022-08-09

Last Posted Date: 2022-10-21

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 29

Registration Number: NCT05493683

Locations: 🇨🇳
Changzhou NO.2 People's Hospital, Changzhou, Jiangsu, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy